|
Synonyms: BIVV009 | Enjaymo® | IPN-009 | IPN009 | sutimlimab-jome | TNT009
sutimlimab is an approved drug (EMA & FDA (2022))
Compound class:
Antibody
Comment: Sutimlimab (TNT009) is a humanised, monoclonal antibody that is designed to selectively inhibit the classical complement pathway by targeting C1s [3]; C1s being the serine protease component of the C1-complex in the complement pathway of the immune system. It prevents hemolysis. Sutimlimab is claimed in True North Therapeutics' patent WO2016164358A1 [4] and is likely to be the antibody designated as VH4/VK2 based on peptides matches between those provided in the submission to the WHO for INN sutimlimab and those in the patent application (namely SEQ IDs NOs 42 and 44). The research code TNT009 was changed to BIVV009 when True North Therapeutics were acquired by Bioverativ (a Sanofi company) in 2017, and clinical trials are ongoing using both of these code names.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| References |
|
1. Eskandary F, Jilma B, Mühlbacher J, Wahrmann M, Regele H, Kozakowski N, Firbas C, Panicker S, Parry GC, Gilbert JC et al.. (2018)
Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial. Am J Transplant, 18 (4): 916-926. [PMID:28980446] |
|
2. Mühlbacher J, Jilma B, Wahrmann M, Bartko J, Eskandary F, Schörgenhofer C, Schwameis M, Parry GC, Gilbert JC, Panicker S et al.. (2017)
Blockade of HLA Antibody-Triggered Classical Complement Activation in Sera From Subjects Dosed With the Anti-C1s Monoclonal Antibody TNT009-Results from a Randomized First-in-Human Phase 1 Trial. Transplantation, 101 (10): 2410-2418. [PMID:28926521] |
|
3. Nikitin PA, Rose EL, Byun TS, Parry GC, Panicker S. (2019)
C1s Inhibition by BIVV009 (Sutimlimab) Prevents Complement-Enhanced Activation of Autoimmune Human B Cells In Vitro. J Immunol, 202 (4): 1200-1209. [PMID:30635392] |
|
4. Panicker S, Parry G. (2016)
Humanized anti-c1s antibodies and methods of use thereof. Patent number: WO2016164358A1. Assignee: True North Therapeutics, Inc.. Priority date: 06/04/2015. Publication date: 05/04/2016. |
|
5. Wahrmann M, Mühlbacher J, Marinova L, Regele H, Huttary N, Eskandary F, Cohen G, Fischer GF, Parry GC, Gilbert JC et al.. (2017)
Effect of the Anti-C1s Humanized Antibody TNT009 and Its Parental Mouse Variant TNT003 on HLA Antibody-Induced Complement Activation-A Preclinical In Vitro Study. Am J Transplant, 17 (9): 2300-2311. [PMID:28251805] |
